158 Clinical Performance of a Novel Point-of-Care Coagulometer, the Perosphere ClotChek™, for the DOACS

158 Clinical Performance of a Novel Point-of-Care Coagulometer, the Perosphere ClotChek™, for the DOACS

Saved in:

Bibliographic Details
Main Authors:	S.H. Bakhru, X. Jiang, L. Chen, D. Osmani, A. Balaj, K. Kronen, D. Mootoo, F. LaDuca, J. Ansell
Format:	Article
Language:	English
Published:	Elsevier 2025-05-01
Series:	Research and Practice in Thrombosis and Haemostasis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2475037925001104
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Validation of a whole blood coagulometer sensitive to the direct oral anticoagulants
by: Sasha H. Bakhru, et al.
Published: (2025-03-01)

Detection of enoxaparin and argatroban by use of the novel viscoelastic coagulometer ClotPro
by: Johannes Gratz, et al.
Published: (2024-11-01)

Influence of DOACS and DOAC-REMOVE® on coagulation assays during thrombophilia testing in DOAC-treated patients
by: Kovač Mirjana, et al.
Published: (2022-01-01)

P305: CHEK2 and pediatric cancer predisposition
by: Joyce Turner, et al.
Published: (2025-01-01)

Viscoelastic Point-of-Care Testing (ClotPro<sup>®</sup>) to Guide Intravenous Thrombolysis in Acute Ischemic Stroke Patients on DOACs: Replacing History with Hemostasis in a Proof-of-Concept Study
by: Jessica Seetge, et al.
Published: (2025-07-01)

PO93 | Use of DOACS in heart transplantation recipients
Published: (2025-08-01)

DOAC Score for Predicting Clinical Outcomes After Left Atrial Appendage Closure
by: Masahiko Asami, MD, et al.
Published: (2025-04-01)

To clot, or not to clot – Antithrombotic therapy is the question
by: E. Osuch, et al.
Published: (2019-07-01)

PO53 | Effectiveness and safety of DOACS in patients with renal transplantation
Published: (2025-08-01)

Characteristics of chronic subdural haematomas related to DOACs vs warfarin
by: Gokul Raj Krishna, et al.
Published: (2025-04-01)

Direct oral anticoagulants (DOACs): From the laboratory point of view
by: Margetić Sandra, et al.
Published: (2022-12-01)

2022 CVS Caremark DOAC non-medical switch: Patient ramifications and physician advocacy
by: Kushal D. Patel, et al.
Published: (2024-12-01)

Otsenka effektivnosti i bezopasnosti ispol'zovaniya insulinovykh pomp Accu-Chek
by: Andrey Olegovich Emel'yanov, et al.
Published: (2008-09-01)

Cohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands – Hebon-CHEK2
by: Rosa de Groot, et al.
Published: (2024-10-01)

156 Continued Assessment of a Direct Oral Anticoagulant (DOAC) Dashboard
by: Nghi Ha, et al.
Published: (2025-05-01)

Dependence of clot structure and fibrinolysis on apixaban and clotting activator
by: Rebecca A. Risman, et al.
Published: (2024-11-01)

CHEK1 is a synthetic lethal interactor of FBXO7 in colonic epithelial cells
by: Tooba Razi, et al.
Published: (2025-09-01)

Safety of DOACs in patients with Child‐Pugh Class C cirrhosis and atrial fibrillation
by: Mark Ayoub, et al.
Published: (2024-05-01)

Comparison between DOACs and warfarin for left atrial thrombus in atrial fibrillation patients
by: Akihiro Sunaga, et al.
Published: (2025-08-01)

Description of energy levels and decay properties in 158Gd nucleus
by: Fahmi Sh. Radhi, et al.
Published: (2023-09-01)

Clinical Application of Clot Waveform Analysis
by: Hideo Wada MD, PhD, et al.
Published: (2025-04-01)

Recurrent Germline Mutations of CHEK2 as a New Susceptibility Gene in Patients with Pheochromocytomas and Paragangliomas
by: Yinjie Gao, et al.
Published: (2021-01-01)

Unresectable endocrine mucin-producing sweat gland carcinoma revealing an actionable somatic CHEK2 gene mutation
by: S. Tzoumpa, et al.
Published: (2024-01-01)

白癜风158例临床分析
Published: (2011-01-01)

76 The Impact of a VA DOAC Population Management Tool Flag for Concurrent Antiplatelets
by: Allison B. Riendeau, et al.
Published: (2025-05-01)

High rate of mutations in the BRCA1, BRCA2, CHEK2, NBN, and BLM genes in Russian ovarian cancer patients
by: Ye. I. Bateneva, et al.
Published: (2015-01-01)

VIDEOTHORACOSCOPY FOR CLOTTED HEMOTHORAX IN PATIENTS WITH PENETRATING CHEST TRAUMA
by: O. V. Voskresensky, et al.
Published: (2016-03-01)

Rapid Blood Clot Removal via Remote Delamination and Magnetization of Clot Debris
by: Qinglong Wang, et al.
Published: (2025-05-01)

Red blood cell aggregation within a blood clot causes platelet-independent clot shrinkage
by: Alina D. Peshkova, et al.
Published: (2025-07-01)

DISMISSAL PROTECTION IN THE BRICS COUNTRIES IN LIGHT OF ILO CON VENTION No. 158
by: E. Sychenko, et al.
Published: (2019-11-01)

Challenges in warfarin versus DOACs for elderly atrial fibrillation: A critique of Takagi and Ueda's study
by: Sanjana, et al.
Published: (2025-06-01)

70 Evaluation of Current Outpatient DOAC Management Practices Within Trinity Health Grand Rapids
by: Ashlyn Kiebach, et al.
Published: (2025-05-01)

Direct oral anticoagulant (DOAC) monitoring within primary care: a quality improvement project
by: Isobel Joy McFadzean, et al.
Published: (2023-06-01)

Osteocalcin and GPR158: linking bone and brain function
by: Jingjing Li, et al.
Published: (2025-04-01)

The Decision on Obviating Investigations (CPC Art. 158/6)
by: Berrin Akbulut
Published: (2022-06-01)

Direct oral anticoagulants (DOACs) for postoperative venous thromboembolism prophylaxis in patients with gynecologic malignancies: A quality mini-review
by: Peter W. Ketch, et al.
Published: (2024-12-01)

BLOOD CLOTTING NUMERICAL SIMULATION
by: E. M. Lashkevich, et al.
Published: (2019-06-01)

CLOTTING DISORDERS IN MULTIPLE TRAUMA
by: R. M. Gabdulkhakov, et al.
Published: (2018-01-01)

PROTEOLYTIC ACTIVITY OF MILK-CLOTTING ENZYMES OF DIFFERENT ORIGIN
by: D. S. Myagkonosov, et al.
Published: (2022-03-01)

Clinical impact of inappropriate DOAC dosing in atrial fibrillation: Insights from a real-world registry
by: Mustafa Yildirim, et al.
Published: (2025-02-01)